. Introduction {#s01}
==============

Breast cancer (BCa) is a heterogeneous disease, and approximately 75% of all BCa cases show overexpression of estrogen receptors (ER) and/or progesterone receptors (PR)^[@b1]^. The estrogen pathway affects the expression of hundreds of genes involved in proliferation, differentiation, survival, invasion, metastasis, and angiogenesis, all of which are particularly relevant to cancer^[@b2]^.

Apart from surgery, endocrine therapy is considered a complementary treatment in most patients and has shown consistent clinical benefits, particularly for ER-positive patients with respect to inducing tumor remission^[@b3]^. Among all endocrine therapies, tamoxifen is the most extensively used drug and functions as a selective ER modulator^[@b4]^ that competitively blocks estrogen binding^[@b5]^. However, many breast tumors show either primary resistance to endocrine therapies or develop secondary resistance after initial responsiveness^[@b6]-[@b10]^. Approximately 20%--30% of patients who received adjuvant tamoxifen experienced relapse, and most patients with advanced disease who showed an initially positive response to tamoxifen eventually experienced disease progression^[@b11]^. The mechanism of this resistance involves cross-talk between ER and alternative signaling pathways involved in cell survival and proliferation, such as those for epidermal growth factor receptor and human epidermal growth factor receptor 2^[@b12]-[@b15]^.

Melanoma differentiation-associated gene 9 was discovered through screening of differentially expressed genes upon treatment of melanoma^[@b16]^. This protein, also known as syntenin, interacts with syndecan family members and is therefore also known as syndecan-binding protein (SDCBP). The syndecan family belongs to a group of cell surface molecules and is involved in cell--cell and cell--matrix adhesion. SDCBP has a total of 298 amino acids and contains two PDZ domains, PDZ-1 (amino acids 110--193) and PDZ-2 (amino acids 194--274)^[@b17]^. The PDZ domain is found in a family of proteins that controls diverse and central physiologic processes such as migration and lipid binding^[@b18]-[@b20]^. Through cross-talk with protein kinase C alpha via adhesion-mediated activation downstream of the fibronectin signal, SDCBP activates focal adhesion kinase to take part in cellular migration and invasive BCa development^[@b21]^. Moreover, activation of integrin β1 and extracellular signal-related kinase 1/2 was shown to be required for syntenin-mediated migration and invasion of BCa cells^[@b22]^.

Our previous study showed that SDCBP expression was positively correlated with histologic grade and tumor staging, but negatively correlated with ERα expression. In ER-negative BCa cells, SDCBP silencing increased cell populations in G1 phase of the cell cycle and resulted in up-regulation of p21 and p27 while down-regulating cyclin E, thereby arresting the cell cycle and prohibiting cell proliferation^[@b23]^. In the present study, we examined the effects of SDCBP on ER- positive BCa cells. To determine the role of SDCBP expression in ER-positive BCa development and whether SDCBP down-regulation can be used as a targeted treatment, we evaluated the expression profile of SDCBP in ER-positive cases. Using the RNAi technique, we analyzed the mechanisms underlying the involvement of SDCBP in ER-positive BCa development and its correlation with the estrogen-signaling pathway as well as its impact on endocrine therapy.

. Material and methods {#s02}
======================

. Sample collection {#s02.01}
-------------------

ER-positive breast tissue samples (*n* = 99) were obtained from patients who underwent surgical excision at the Department of Breast Cancer Pathology and Research Laboratory at Tianjin Medical University Cancer Institute and Hospital (China) from January to March of 2010. These samples were used in our previous study^[@b23]^.

. Immunohistochemistry {#s02.02}
----------------------

Staining of ERα, PR, and SDCBP was performed as described in our previous publication^[@b23]^. [**Table S1**](#TableS1){ref-type="table"} lists information regarding the antibodies used.

###### 

Detailed information for antibodies used in this work.

  Name                         Type                Supplier                          Catalog \#   Origin               Dilution ratio   
  ---------------------------- ------------------- --------------------------------- ------------ -------------------- ---------------- ------
  Cyclin D1 Antibody (H-295)   Rabbit polyclonal   Santa Cruz Biotechnology, Inc.    sc-753       Dallas, TX, U.S.A.   1:1000           
  Cyclin E Antibody (M-20)     Rabbit polyclonal   Santa Cruz Biotechnology, Inc.    sc-481       Dallas, TX, U.S.A.   1:1000           
  β-Actin Antibody (C4)        mouse monoclonal    Santa Cruz Biotechnology, Inc.    sc-47778     Dallas, TX, U.S.A.   1:1500           
  p27 Kip1 (D69C12)            Rabbit monoclonal   Cell Signaling Technology, Inc.   \#3686       Danvers, MA, U.S.A   1:1000           
  p21 Waf1/Cip1 (12D1)         Rabbit monoclonal   Cell Signaling Technology, Inc.   \#2947       Danvers, MA, U.S.A   1:1000           
  ERα antibody (6F11)          mouse monoclonal    Thermo Fisher Scientific Inc.     MA5-13304    MA, U.S.A                             1:50
  PR antibody (SP2)            Rabbit monoclonal   Thermo Fisher Scientific Inc.     MA5-14505    MA, U.S.A                             1:50
  Syntenin-1 Antibody (N-20)   goat polyclonal     Santa Cruz Biotechnology, Inc.    sc-19379     Dallas, TX, U.S.A    1:500            1:75
  Phospo-Rb (S780)             goat polyclonal     Santa Cruz Biotechnology, Inc.    sc-12901     Dallas, TX, U.S.A    1:500            

The expression levels of ERα, PR, and SDCBP were semi-quantified using a modified scoring system, where the intensity score (0 = negative; 1 = low; 2 = medium; 3 = high) was multiplied by the percentage of cells that were stained. This scoring system gives a final score ranging from 0 to 300. In the presence of cytoplasmic staining, SDCBP status was classified according to this modified scoring system: negative (0--50), weak (51--100), moderate (101--200), or strong (201--300). ERα and PR status were categorized in the same manner as SDCBP signals in the presence of nuclear staining. All cases were evaluated by two pathologists independently and any discrepancy was resolved by group discussion. The PR/ERα ratio was calculated as the PR staining score/ERα staining score. The correlation between SDCBP status and pathologic features were analyzed using a non-parametric Spearman correlation test.

. Cell culture {#s02.03}
--------------

The human BCa cell lines MCF-7 and T47D were purchased from American Type Culture Collection (ATCC® HTB-22^TM^ and ATCC® HTB-133 respectively, Manassas, VA, USA).

To deplete estrogen, cells were cultured in phenol red-free RPMI 1640 containing 2.5% HyClone Charcoal/Dextran-Treated Fetal Bovine Serum (SH30068.03, Thermo Scientific, Waltham, MA, USA) for 24 h. Next, 17-β estradiol (E2, Sigma-Aldrich, St. Louis, MO, USA) in ethanol was added to the culture medium at a final concentration of 0, 0.1, 1, or 10 nM, and the cells were cultured for another 24 h. Tamoxifen was purchased from Sigma and added to the culture medium at a final concentration of 2 μM.

. Real-time quantitative reverse transcriptase PCR (qRT-PCR) {#s02.04}
------------------------------------------------------------

Total RNA extraction was performed as previously reported^[@b23]^. Primers for pS2, PR, and SDCBP are listed in [**Table S2**](#TableS2){ref-type="table"} and β-actin was used as an internal control. The real-time qRT-PCR assay was performed using an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). pS2 and PR mRNA transcription levels were normalized against β-actin mRNA expression.

###### 

Primers for semi-quantitative and real-time quantitative reverse transcription-PCR.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Official symbol\   Genebank No.   Amplified fragment length (bp)   Annealing temperature (°C)   Primer name       Sequence (from 5′ to 3′)
  of target gene                                                                                                    
  ------------------ -------------- -------------------------------- ---------------------------- ----------------- ---------------------------
  pS2                X00474         356                              56.2                         pS2 foward        CATGGAGAACAAGGTGATCTG

                                                                                                  pS2 reverse       CAGAAGCGTGTCTGAGGTGTC

  PR                 NM_001278456   320                              55.6                         PR foward         CCATGTGGCAGATCCCACAGGAGTT

                                                                                                  PR reverse        TGGAAATTCAACACTCAGTGCCCGG

  β-actin            NM_001101      194                              55.9                         β-actin forward   GTCACCAACTGGGACGACAT

                                                                                                  β-actin reverse   AGCACAGCCTGGATAGCAAC
  ---------------------------------------------------------------------------------------------------------------------------------------------

. Establishment of SDCBP- silenced MCF-7 cells {#s02.05}
----------------------------------------------

The shRNA used to silence SDCBP and negative control shRNA are listed in [**Table S3**](#TableS3){ref-type="table"} \[both were designed by Genepharma Co., Ltd (Shanghai, China)\]. The procedures for screening the SDCBP-silenced stable MCF-7 cell line were performed as previously reported^[@b23]^. Subcultures showing maximal SDCBP silencing were designated as "MCF-7 shRNA", while control shRNA-transfected subcultures were designated as "MCF-7 NC".

###### 

The target sequence for short-hairpin RNA design of syndecan-binding protein (SDCBP)

  Target site        Target sequence (from 5′ to 3′)
  ------------------ ---------------------------------
  Negative control   AATTCTCCGAACGTGTCACGT
  611\#              GGGACCAAGTACTTCAGATCA

. SDCBP-overexpression BCa cell line construction {#s02.06}
-------------------------------------------------

SDCBP-overexpressing and control cell lines were constructed as described previously^[@b24]^. Corresponding exogenous protein overexpression was evaluated by Western blot after the cells were cultured for 8 and 6 weeks for MCF-7 and T47D cells, respectively, in the appropriate medium containing 0.5 mg/mL of G418 (Sigma-Aldrich).

. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay {#s02.07}
--------------------------------------------------------------------------

The MTT assay was performed as previously reported^[@b23]^, except that MCF-7 and T47D cells were seeded at 2,000 and 1,500 cells per well in a 96-well plate, respectively.

. Flow cytometric cell-cycle analysis {#s02.08}
-------------------------------------

Cell-cycle analysis was performed on a BD FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) as described previously^[@b25]^.

. Western blot assay {#s02.09}
--------------------

Holoproteins in cell lysates were extracted, quantified, and immunoblotted as previously described^[@b23]^. The information and usage of antibodies are listed in [**Table S1**](#TableS1){ref-type="table"}. Protein expression levels were quantified using intensities normalized to β-actin. The expression levels calculated from three repeated immunoblots of all groups followed a normal distribution and were presented as the mean ± standard deviation. Student's *t*-test was used to examine differences between groups.

. Luciferase assay {#s02.10}
------------------

Cells were co-transfected with the ERα luciferase reporter plasmid PGMER-Lu (Genomeditech Co., Ltd., Shanghai, China) and wide-type Renilla luciferase reporter gene control plasmid pGMR-TK in 24-well plates. Luciferase activities in cell lysates were measured using the Dual-Luciferase Reporter Assay in triplicate and normalized to Renilla luciferase activity. pGM-CMV-Lu-transfected cells were used as positive controls and the average relative luciferase activity of transfected MCF-7 NC/MCF-7 Neo/T47D Neo cells was defined as "1". Student's *t* test was used to examine the differences between these normally distributed groups.

. Results {#s03}
=========

. Silenced/overexpressed SDCBP influences the effects of tamoxifen on BCa proliferation {#s03.01}
---------------------------------------------------------------------------------------

As shown in [**Figure 1A**](#Figure1){ref-type="fig"}, SDCBP shRNA silenced most target proteins compared to MCF-7 NC in either the presence or absence of tamoxifen. However, SDCBP silencing alone did not affect cellular proliferation in the absence of tamoxifen, but rather enhanced the suppressive effect of tamoxifen ([**Figure 1B**](#Figure1){ref-type="fig"}). Although SDCBP silencing did not affect MCF-7 cell-cycle kinetics in the absence of tamoxifen, it consistently contributed to the arrest of more cells in G1 in the presence of tamoxifen (*P* \< 0.001, [**Figure 1C**](#Figure1){ref-type="fig"}).

As shown in [**Figure 1D**](#Figure1){ref-type="fig"} and [**1G**](#Figure1){ref-type="fig"}, SDCBP was significantly overexpressed in both MCF-7 and T47D cells; SDCBP overexpression accelerated cellular proliferation in both the absence and presence of tamoxifen in both cell lines. Under conditions of SDCBP overexpression, the effect of tamoxifen on cell proliferation was significantly attenuated ([**Figure 1E**](#Figure1){ref-type="fig"} and [**1H**](#Figure1){ref-type="fig"}). Accordingly, in both cell lines, SDCBP overexpression reduced cells in G1 phase in both the absence and presence of tamoxifen and weakened the effects of tamoxifen on the cell cycle ([**Figure 1F**](#Figure1){ref-type="fig"} and [**1I**](#Figure1){ref-type="fig"}).

![Effect of tamoxifen treatment and SDCBP silencing/overexpressing on proliferation of ER-positive breast cancer cells.](cbm-15-1-29-1){#Figure1}

. Effects of SDCBP silencing/overexpressing on cell-cycle regulators in MCF-7 cells in the presence of tamoxifen {#s03.02}
----------------------------------------------------------------------------------------------------------------

In ER-positive MCF-7 cells, tamoxifen treatment alone significantly increased p21 levels but attenuated the levels of phosphorylated Rb and cyclin D1. However, SDCBP silencing alone did not influence levels of p21, p27, cyclin D1, cyclin E, or phosphorylated Rb. In contrast, SDCBP silencing significantly up-regulated the levels of p21 and p27, but down-regulated the levels of phosphorylated Rb and cyclin E beyond that of tamoxifen alone. However, SDCBP silencing failed to further decrease cyclin D1 compared to tamoxifen alone ([**Figure 2A**](#Figure2){ref-type="fig"}--[**2G**](#Figure2){ref-type="fig"}). SDCBP overexpression alone did not influence p21 levels, but significantly down-regulated p27. Tamoxifen treatment did not recover the levels of p27, but up-regulated the levels of p21 under conditions of SDCBP overexpression ([**Figure 2H**](#Figure2){ref-type="fig"}--[**2K**](#Figure2){ref-type="fig"}).

![Effect of tamoxifen treatment and SDCBP silencing/overexpression on G1/S cell-cycle regulators.](cbm-15-1-29-2){#Figure2}

. Effects of SDCBP silencing/overexpression on estrogen responsiveness in ER-positive BCa cell line {#s03.03}
---------------------------------------------------------------------------------------------------

The luciferase assay suggested that SDCBP silencing enhanced the estrogenic response when E2 was administrated at concentrations between 0.1 and 10 nM compared to MCF-7 NC counterparts (*P* = 0.017, *P* = 0.020 and *P* = 0.002, respectively) ([**Figure 3A**](#Figure3){ref-type="fig"}). qRT-PCR evaluation showed that SDCBP silencing up-regulated pS2 and PR by 40.0% and 62.3% at the mRNA level, respectively, compared to those in MCF-7 NC cells incubated with 10 nM E2 (*P* = 0.026 and *P* = 0.0011, respectively) ([**Figure 3B**](#Figure3){ref-type="fig"} and [**3C**](#Figure3){ref-type="fig"}). The enhanced effect of SDCBP silencing on pS2 and PR transcription depended upon the presence of estrogen, as transcriptional levels were unaffected in the absence of estrogen (*P* = 0.847 and *P* = 0.413, respectively).

In contrast, the luciferase assay suggested that SDCBP overexpression in MCF-7 or T47D cells attenuated the estrogenic response compared to their MCF-7 and T47D Neo counterparts, respectively ([**Figure 3D**](#Figure3){ref-type="fig"} and [**3G**](#Figure3){ref-type="fig"}). qRT-PCR showed that SDCBP overexpression resulted in down-regulation of pS2 and PR in MCF-7 cells (51.6% and 28.1%, respectively) ([**Figure 3E**](#Figure3){ref-type="fig"} and [**3F**](#Figure3){ref-type="fig"}) and T47D cells (33.7% and 19.8%, respectively) ([**Figure 3H**](#Figure3){ref-type="fig"} and [**3I**](#Figure3){ref-type="fig"}) when incubated with 10 nM E2.

![Effects of SDCBP silencing/overexpression on estrogenic responses.](cbm-15-1-29-3){#Figure3}

. Clinical pathologic characters of ER-positive BCa cases and their correlations with SDCBP expression {#s03.04}
------------------------------------------------------------------------------------------------------

Correlations between pathologic characters and SDCBP expression were examined in ER-positive BCa tissues (*n* = 99). Among PR-negative tumors, 26.3% (5/19) demonstrated strong SDCBP staining ([**Table 1**](#Table1){ref-type="table"}), while no tumors staining strongly positive for PR (0/26) showed strong positive staining for SDCBP ([**Table 1**](#Table1){ref-type="table"}). Negative correlations between SDCBP expression and PR status or the PR/ERα ratio were also established (R~S~ = --0.37, *P* \< 0.001; and R ~S~ = --0.24, *P* = 0.017, respectively) ([**Figure 4**](#Figure4){ref-type="fig"} and [**Table 1**](#Table1){ref-type="table"}). This experiment also showed that SDCBP expression was negatively correlated with ERα (R~S~ = --0.29, *P* = 0.004) ([**Table 1**](#Table1){ref-type="table"}). There were no significant differences among the different levels of SDCBP staining in lymph node involvement and pTNM stage ([**Table 1**](#Table1){ref-type="table"}). Detailed information for each case is shown in [**Table S4**](#TableS4){ref-type="table"}.

![ERα, PR, and SDCBP expression in ER-positive breast cancer tissue.](cbm-15-1-29-4){#Figure4}

###### 

Correlation of SDCBP expression with pathologic features in ER-positive breast cancers

  Pathological features   Cases   Syndecan binding protein (%)   *r*~s~        *P*\*                                
  ----------------------- ------- ------------------------------ ------------- ------------- ------------- -------- ---------
  Lymph node status                                                                                        0.08     0.441
  　Negative              52      15 (28.8)                      24 (46.2)     8 (15.4)      5 (9.6)                
  　Positive              47      12 (25.5)                      18 (38.3)     14 (29.8)     3 (6.4)                
  pTNM stage                                                                                               0.17     0.101
  　I                     33      10 (30.3)                      14 (42.4)     5 (15.2)      4 (12.1)               
  　II                    47      14 (29.8)                      24 (51.1)     8 (17.0)      1 (2.1)                
  　III--Ⅳ                19      3 (15.8)                       4 (21.1)      9 (47.4)      3 (15.8)               
  PR status                                                                                                --0.37   \<0.001
  　Negative              19      2 (10.5)                       5 (26.3)      7 (36.8)      5 (26.3)               
  　Weak                  15      4 (26.7)                       4 (26.7)      5 (33.3)      2 (13.3)               
  　Moderate              39      13 (33.3)                      17 (43.6)     8 (20.5)      1 (2.6)                
  　Strong                26      8 (30.8)                       16 (61.5)     2 (7.7)       0 (0.0)                
  ERα status                                                                                               --0.29   0.004
  　Weak                  30      7 (23.3)                       8 (26.7)      8 (26.7)      7 (23.3)               
  　Moderate              24      5 (20.8)                       11 (45.8)     7 (29.2)      1 (4.2)                
  　Strong                45      15 (33.3)                      23 (51.1)     7 (15.6)      0 (0.0)                
  PR/ERα ratio^a^                                                                                          --0.24   0.017
  　Cases                 99      27                             42            22            8                      
                                  0.94 (0.72)                    0.92 (0.60)   0.65 (1.02)   0.29 (0.85)            

###### 

Detailed features of 99 consecutive cases of estrogen receptor (ER)-positive breast cancer from January to March of 2010.

  SDCBP status   PR scoring   PR status   ERα scoring   ERα status   PR/ER ratio   Lymph node status   pTNM staging
  -------------- ------------ ----------- ------------- ------------ ------------- ------------------- --------------
  Negative       160          Moderate    55            Weak         2.91          Negative            I
  Negative       65           Weak        60            Weak         1.08          Positive            II
  Negative       150          Moderate    70            Weak         2.14          Negative            II
  Negative       30           Negative    80            Weak         0.38          Negative            I
  Negative       80           Weak        85            Weak         0.94          Positive            II
  Negative       20           Negative    90            Weak         0.22          Positive            II
  Negative       120          Moderate    100           Weak         1.2           Positive            II
  Negative       270          Strong      135           Moderate     2             Positive            II
  Negative       180          Moderate    140           Moderate     1.29          Negative            I
  Negative       130          Moderate    150           Moderate     0.87          Negative            II
  Negative       270          Strong      160           Moderate     1.69          Positive            III--IV
  Negative       75           Weak        165           Moderate     0.45          Negative            I
  Negative       270          Strong      210           Strong       1.29          Negative            I
  Negative       270          Strong      210           Strong       1.29          Negative            II
  Negative       180          Moderate    210           Strong       0.86          Positive            II
  Negative       140          Moderate    210           Strong       0.67          Negative            I
  Negative       120          Moderate    210           Strong       0.57          Negative            II
  Negative       120          Moderate    210           Strong       0.57          Positive            II
  Negative       270          Strong      225           Strong       1.2           Negative            II
  Negative       240          Strong      225           Strong       1.07          Negative            I
  Negative       120          Moderate    225           Strong       0.53          Positive            III--IV
  Negative       95           Weak        225           Strong       0.42          Negative            I
  Negative       240          Strong      240           Strong       1             Negative            I
  Negative       190          Moderate    240           Strong       0.79          Positive            II
  Negative       160          Moderate    255           Strong       0.63          Positive            II
  Negative       270          Strong      285           Strong       0.95          Positive            III--IV
  Negative       160          Moderate    285           Strong       0.56          Negative            I
  Weak           165          Moderate    55            Weak         3             Negative            II
  Weak           120          Moderate    55            Weak         2.18          Positive            II
  Weak           140          Moderate    55            Weak         2.55          Negative            II
  Weak           110          Moderate    60            Weak         1.83          Positive            II
  Weak           0            Negative    75            Weak         0             Negative            I
  Weak           90           Weak        80            Weak         1.13          Positive            II
  Weak           25           Negative    80            Weak         0.31          Positive            II
  Weak           55           Weak        90            Weak         0.61          Positive            II
  Weak           70           Weak        110           Moderate     0.64          Negative            I
  Weak           270          Strong      120           Moderate     2.25          Negative            II
  Weak           60           Weak        125           Moderate     0.48          Negative            I
  Continued                                                                                            

. Discussion {#s04}
============

Tamoxifen is the most commonly used chemotherapeutic agent for patients with ER-positive BCa^[@b26]^, and tamoxifen resistance poses great challenges to BCa treatment. Some patients have presented with intrinsic resistance regardless of showing high levels of ER, while other patients initially respond to tamoxifen but later develop acquired resistance^[@b27]^.

Our previous study showed that expression of SDCBP can be attenuated by estrogen^[@b23]^; in the present study, we found that silencing of SDCBP enhances the inhibitory effect of tamoxifen with regard to cellular proliferation and cell-cycle progression in ER/PR-positive MCF-7 cells. This indicates that SDCBP drives cell proliferation and cell-cycle progression by up-regulating self-expression and activating alternative signaling pathways when estrogen signaling is inhibited. Under conditions of SDCBP overexpression, the function of tamoxifen on cell proliferation was significantly attenuated, suggesting that SDCBP overexpression leads to tamoxifen resistance in ER-positive BCa. Notably, SDCBP silencing alone did not affect cell proliferation or the expression of molecules that control the cell cycle in ER-positive MCF-7 cells; however, SDCBP overexpression accelerated cellular proliferation in both the absence and presence of tamoxifen. This indicates that ER signaling counteracts some of the SDCBP-signaling lost in malignancy development.

In MCF-7 cells, under estrogen-signaling pathway activation, cellular proliferation and cell-cycle progression (including G1/S checkpoint-related regulators) showed no obvious changes when SDCBP expression was silenced by RNA interference. It has been reported that activated estrogen signaling can accelerate cell-cycle progression by limiting p21 expression, increasing phosphorylation levels of Rb protein, and promoting cyclin D1 expression^[@b28]^, all of which are consistent with our results. In contrast, SDCBP silencing further up-regulated the expression of p21 and p27 while down-regulating phosphorylation levels of Rb and expression of cyclin E in MCF-7 cells in the presence of tamoxifen, similar to the effects of SDCBP silencing alone in triple-negative BCa cell lines. Interestingly, SDCBP silencing can either exert its effect in the presence of tamoxifen (such as by promoting p27 expression and inhibiting cyclin E expression) or augment the effect of tamoxifen (such as by further promoting p21 expression and inhibiting phosphorylation levels of Rb), but SDCBP silencing does not change cyclin D1 expression markedly beyond that of tamoxifen alone. SDCBP overexpressing alone did not influence the levels of p21 but significantly down-regulated p27. Tamoxifen treatment did not recover the levels of p27, but up-regulated the levels of p21 under conditions of SDCBP overexpression. This indicates that when the estrogen signal is restrained, SDCBP not only partially substitutes for the estrogen signal, but also is involved in some other regulating mechanism(s) of cell-cycle progression. In the absence of tamoxifen, because SDCBP silencing up-regulates the estrogenic response as shown in [**Figure 3**](#Figure3){ref-type="fig"}, the up-regulation tendency of p21 and p27 may be counteracted by a larger estrogenic response; however, in the absence of tamoxifen, this counteraction was eliminated. This may partly explain why SDCBP silencing alone did not alter the levels of p21 and p27, while these levels were changed with tamoxifen. We also predicted that p21 levels depend more on the estrogen pathway than on SDCBP in ER-positive BCa cells; however, p27 levels may be closely related to the interaction between SDCBP and c-src as previously reported in triple-negative breast cancer cells^[@b24]^. In addition, SDCBP silencing enhances the effects of tamoxifen and may be useful as a targeted treatment in ER-positive BCa.

PR is an ER-regulated gene that mediates the effects of progesterone on the development of both the normal mammary gland and BCa^[@b29]^. Compared to ER/PR double-positive BCa, patients with BCa who are ER-positive but PR-negative suffered a poorer prognosis and were more prone to developing resistance against endocrine treatment^[@b30]-[@b32]^. The 21-gene recurrence score assay (Oncotype DX®) is a multigene assay used to predict the recurrence of tamoxifen-treated, node-negative BCa. In this scoring system, the ER group score is negatively correlated with cancer recurrence, and PR carries even more weight than ER in the ER group score^[@b33]^. The pS2 gene was originally identified as an estrogen-inducible transcript in the human BCa cell line MCF-7 and was shown to be a direct target of ERs^[@b34],[@b35]^. Our study showed that SDCBP silencing enhanced the estrogen response of MCF-7 cells and further elevated the expression levels of PR and pS2 in response to estrogen, while its overexpression had the opposite effect in both MCF-7 and T47D cells, indicating a role for SDCBP in suppressing estrogenic responses. As indicated by immunohistochemistry analysis, the expression level of SDCBP was negatively correlated with PR status and the PR/ERα ratio. This supports that SDCBP negatively regulates the estrogenic response and may play an important role in developing resistance to endocrine treatment in ER-positive BCa. These results also suggest that SDCBP silencing can be applied as a targeted treatment in ER-positive BCa.

In conclusion, SDCBP promotes cell cycle progression in ER-positive BCa, particularly when the estrogen-signaling pathway is blocked. It also negatively regulates the estrogen response in ER-positive BCa, but its underlying molecular mechanism of action and related signaling pathway(s) remain unclear. Silencing of SDCBP or its downstream signal(s) may improve the therapeutic effect of endocrine treatment in ER-positive BCa, particularly in cases of primary or secondary resistance.
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